KMDA
KamadaNASDAQHEALTHCAREDRUG MANUFACTURERS - SPECIALTY & GENERIC
Key Statistics
Market Cap
$476.98M
P/E Ratio
23.57
EPS
$0.35
Beta
0.31
52W High
$9.07
52W Low
$5.61
50-Day MA
$8.58
200-Day MA
$7.54
Dividend Yield
3.03%
Profit Margin
11.20%
Forward P/E
16.00
PEG Ratio
0.64
About Kamada
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Fundamentals
| Revenue (TTM) | $180.46M |
| Gross Profit (TTM) | $76.41M |
| EBITDA | $39.51M |
| Operating Margin | 7.95% |
| Return on Equity | 7.64% |
| Return on Assets | 4.37% |
| Revenue/Share (TTM) | $3.13 |
| Book Value | $4.66 |
| Price-to-Book | 1.81 |
| Price-to-Sales (TTM) | 2.64 |
| EV/Revenue | 2.278 |
| EV/EBITDA | 10.48 |
| Quarterly Earnings Growth (YoY) | -14.10% |
| Quarterly Revenue Growth (YoY) | 14.50% |
| Shares Outstanding | $57.69M |
| Float | $10.82M |
| % Insiders | 7.20% |
| % Institutions | 48.94% |
Analyst Ratings
Consensus ($13.00 target)
3
BuyData last updated: 4/8/2026